ClinicalTrials.gg
RecruitingNCT04921553TRacKINGUpdated Aug 2, 2021

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

An observational study in Cancer, Cancer Metastatic and NTRK Gene Fusion Overexpression, sponsored by Centre Leon Berard. Recruiting at 41 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-02.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.

This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.

Read the detailed description
  1. Administrative opening of the center
  2. Routine identification of a patients harboring a rare actionable fusion
  3. Patient's inclusion

    • Signature of written informed consent,
    • Declaration by the physician to the coordinating center (using the "Physician declaration" form)
    • Completion of the QLQ-C30 questionnaire (at inclusion, at each new treatment and then every 6 months).
  4. Collection of retrospective and prospective data into the e-CRF by a local CRA using patients' medical files.
02

Conditions studied

  • Cancer
  • Cancer Metastatic
  • NTRK Gene Fusion Overexpression
  • NTRK Family Gene Mutation
  • ATIC-ALK Fusion Protein Expression
  • ALK Fusion Protein Expression
  • BCR-FGFR1 Fusion Protein Expression
  • ROS1 Gene Translocation
  • COL1A1-PDGFB Fusion Protein Expression
  • RET Gene Translocation
  • Gene Fusion
  • ROS Gene Translocation
  • BRAF Gene Rearrangement
  • FGFR2 Gene Translocation
  • FGFR3 Gene Translocation
  • NTRK1 Gene Translocation

Keywords

  • actionnable fusion
  • cancer
  • registry
  • European reference network
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Leon Berard is the lead sponsor of 211 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patient with histologically-confirmed cancer that harboring a rare actionnable fusion, treated in a European center

Inclusion criteria

  • Patient with -confirmed cancer
  • Patient harboring a rare actionable fusion (see Appendix 1),
  • Availability of clinical and demographic data, information on treatment and clinical outcome.
  • Adult, ≥18 years old,
  • Patient should understand, sign and date the written voluntary form.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • OtherData collection and quality of life questionnaire

    * Data collection from the medical file * Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months

06

What researchers measure

Primary outcomes

  1. Overall Survival

    To describe the survival rate of patients with solid cancers harboring a NTRK fusion or other rare actionable fusion in real-life practice, according to overall survival (OS)

    Time frame: 2 years

Secondary outcomes

  1. Management of patient with actionable fusion

    Treatment scheme : number of line and type of treatments

    Time frame: up to 48 months

  2. Time to relapse

    Time frame: up to 48 months

  3. Progression Free Survival (PFS)

    Time frame: after 6, 12 and 24 months

  4. Incidence of long-term responders

    long term responders =: \> 24 months

    Time frame: up to 48 months

  5. Quality of life of patient

    To evaluate patient-reported outcomes concerning individual QoL according to QLQ-C30 (EORTC Quality of Life questionnaires)

    Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months

  6. Time to relapse for fusion-targeting treatments

    Time frame: up to 48 months

  7. Overall survival for patient treated by fusion-targeting treatments

    Time frame: 2 years

  8. PFS for patient treated by fusion-targeting treatments

    Progression free survival

    Time frame: After 6, 12, 24 months of treatment by fusion targeting treatments

  9. Incidence of long-term responders for patient treated by fusion-targeting treatments

    \> 24 months

    Time frame: up to 48 months

  10. Quality of life of patient treated by fusion-targeting treatments

    using QLQC30 (EORTC Quality of Life questionnaires)

    Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months of fusion-targeting treatments

  11. Safety : Nature of adverse reaction (for treatment targeting a fusion)

    Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

    Time frame: up to 48 months

  12. Safety : Frequency of adverse reaction (for treatment targeting a fusion)

    Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

    Time frame: up to 48 months

  13. Safety : Severity of adverse reaction (for treatment targeting a fusion)

    Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

    Time frame: up to 48 months

07

Study locations

2 of 41 sites recruiting
  • University Hospital Graz
    Graz, Austria
    Not yet recruiting
    • Andreas LEITNER · Principal investigator
  • Medical University of Vienna
    Vienna, Austria
    Not yet recruiting
    • Thomas BRODOWICZ · Principal investigator
  • Masaryk Memorial Cancer Institute (Masarykuv Onkologicky Ustav)
    Brno, Czechia
    Not yet recruiting
    • Jana Halámková · Principal investigator
  • Aarhus University Hospital
    Aarhus, Denmark
    Not yet recruiting
    • Ninna Aggerholm · Principal investigator
  • Chu Jean Minjoz
    Besançon, France
    Not yet recruiting
    • Loic CHAIGNEAU · Principal investigator
  • Institut Bergonie
    Bordeaux, France
    Recruiting
    • Antoine ITALIANO · Principal investigator
  • Centre Georges Francois Leclerc
    Dijon, France
    Not yet recruiting
    • Alice HERVIEU · Principal investigator
  • Centre Oscar Lambret
    Lille, 59020, France
    Not yet recruiting
    • Nicolas PENEL · Principal investigator
  • Chu Dupuytren
    Limoges, France
    Not yet recruiting
    • Valérie LE BRUN LY · Principal investigator
  • Centre Léon Bérard
    Lyon, 69008, France
    Recruiting
  • Assistance Publique Hopitaux de Marseille (AP-HM)
    Marseille, France
    Not yet recruiting
    • Marie Eve GARCIA · Principal investigator
  • Centre Antoine Lacassagne
    Nice, France
    Not yet recruiting
    • Esma SAADA-BOUZID · Principal investigator
  • Institut Curie
    Paris, 75005, France
    Not yet recruiting
    • Sarah WATSON · Contact
    • Sarah WATSON · Principal investigator
  • Aphp - Hopital de La Pitie Salpetriere
    Paris, 75013, France
    Not yet recruiting
    • Jean-Philippe SPANO · Principal investigator
  • Aphp - Hopital Cohin
    Paris, 75014, France
    Not yet recruiting
    • Pascaline BOUDOU-ROUQUETTE · Principal investigator
  • Aphp - Hopital Tenon
    Paris, 75020, France
    Not yet recruiting
    • Jean-Pierre LOTZ · Principal investigator
  • Centre Henri Becquerel
    Rouen, France
    Not yet recruiting
    • Cécile GUILLEMET · Principal investigator
  • Institut Claudius Regaud
    Toulouse, France
    Not yet recruiting
    • Thibaud VALENTIN · Principal investigator
  • "Hämato-Onkologischer Studienkreis MVZ am Klinikum Aschaffenburg / Onkologie"
    Aschaffenburg, Germany
    Not yet recruiting
    • Manfred WELSLAU · Principal investigator
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
    Not yet recruiting
    • Jalid SEHOULI · Principal investigator
  • "Klinik für Innere Medizin III, Hämatologie, Onkologie Klinikum Chemnitz"
    Chemnitz, Germany
    Not yet recruiting
    • Mathias HANEL · Principal investigator
  • "Medizinische Klinik 1- Gastroenterologie, Hepatologie, Pneumologie Universitätsklinikum Frankfurt"
    Frankfurt am main, Germany
    Not yet recruiting
    • Jorg TROJAN · Principal investigator
  • "Hämatologisch-onkologische Ambulanz Universitätsklinikum Halle"
    Halle, Germany
    Not yet recruiting
    • Haifa Kathrin Al-Ali · Principal investigator
  • "Klinik für Gastroenterologie, Hepatologie und Infekt Universitätsklinikum Magdeburg"
    Magdeburg, Germany
    Not yet recruiting
    • Marino Venerito · Principal investigator
  • Mannheim University Medical Center (UniversitatsMedizin Mannheim)
    Mannheim, Germany
    Not yet recruiting
    • Bernd KASPER · Principal investigator
  • "Medizinische Klinik und Poliklinik III LMU - Klinikum der Universität München"
    München, Germany
    Not yet recruiting
    • Volker HEINEMANN · Principal investigator
  • "Klinik für Innere Medizin III, Hämatologie, Onkologie Südharzklinikum"
    Nordhausen, Germany
    Not yet recruiting
    • Hans-Heinrich WOLF · Principal investigator
  • Universitätsklinikum Tübingen Medizinische Universitätsklinik;
    Tübingen, Germany
    Not yet recruiting
    • Constantin Roder · Principal investigator
  • University Hospital Würzburg (UniversitätsKlinikum Würzburg)
    Würzburg, Germany
    Not yet recruiting
    • Volker KUNZMANN · Principal investigator
  • Azienda Ospedaliera - Universitaria - Policlinico S Orsola-Malpighi Univertsita di Bologna
    Bologna, Italy
    Not yet recruiting
    • Maria Abbondenza PANTALEO · Principal investigator
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, Italy
    Not yet recruiting
    • Toni IBRAHIM · Principal investigator
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milano, Italy
    Not yet recruiting
    • Marica EOLI · Principal investigator
  • IRCCS Ospedale San Raffale
    Milano, Italy
    Not yet recruiting
    • Alice BERGAMINI · Principal investigator
  • CRTR-AOU Federico II
    Napoli, Italy
    Not yet recruiting
    • Mario GIULIANO · Principal investigator
  • Azienda Ospedaliero - Universitaria Cita della Salute e della Scienza di Torino
    Torino, Italy
    Not yet recruiting
    • Riccardo SOFFIETTI · Principal investigator
  • Leiden University Medical Center
    Leiden, Netherlands
    Not yet recruiting
    • Ellen KAPITEIJN · Principal investigator
  • Maria Sklodowska Curie National Research Institute of Oncology
    Warsaw, Poland
    Not yet recruiting
    • Iwona LUGOWSKA · Principal investigator
  • Institute of Oncology of Ljubljana
    Ljubljana, Slovenia
    Not yet recruiting
    • Mojca UNK · Principal investigator
  • Complejo Hospitalario regional Virgen del Rocio
    Sevilla, Spain
    Not yet recruiting
    • Javier MARTIN-BROTO · Principal investigator
  • The Royal Marsden NHS Foundation Trust
    London, United Kingdom
    Not yet recruiting
    • Robin JONES · Principal investigator
  • University College London NHS Foundation Trust
    London, United Kingdom
    Not yet recruiting
    • John BRIDGEWATER · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2025, 48 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 48 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Jun 10, 2021
StartActual
Jun 22, 2021
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Aug 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04921553
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
Jun 22, 2021
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Aug 2, 2021

Study contacts

Julien Bollard
Contact
julien.bollard@lyon.unicancer.fr
04 78 78 28 28
Alexandra BIETTE
Contact
alexandra.biette@lyon.unicancer.fr
04 78 78 28 28
Jean-Yves BLAY, Pr
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion